Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Cheryl Crozier"'
Autor:
William Lautert-Dutra, Camila M. Melo, Luiz P. Chaves, Cheryl Crozier, Fabiano P. Saggioro, Rodolfo B. dos Reis, Jane Bayani, Sandro L. Bonatto, Jeremy A. Squire
Publikováno v:
Molecular Cytogenetics, Vol 17, Iss 1, Pp 1-19 (2024)
Abstract Background In prostate cancer (PCa), well-established biomarkers such as MSI status, TMB high, and PDL1 expression serve as reliable indicators for favorable responses to immunotherapy. Recent studies have suggested a potential association b
Externí odkaz:
https://doaj.org/article/506ccc0825c94ba5a2768f71738573d5
Autor:
William Lautert-Dutra, Camila Morais Melo, Luiz Paulo Chaves, Francisco Cesar Sousa, Cheryl Crozier, Dan Dion, Filipe S. Avante, Fabiano Pinto Saggioro, Rodolfo Borges dos Reis, Leticia Fröhlich Archangelo, Jane Bayani, Jeremy A. Squire
Publikováno v:
Cancers, Vol 16, Iss 8, p 1480 (2024)
Prostate cancer (PCa) is an immunologically cold tumor and the molecular processes that underlie this behavior are poorly understood. In this study, we investigated a primary cohort of intermediate-risk PCa (n = 51) using two NanoString profiling pan
Externí odkaz:
https://doaj.org/article/52002b0b87c140f8a4baf6cf34e21906
Autor:
William Lautert-Dutra, Camila M. Melo, Luiz P. Chaves, Francisco C. Souza, Cheryl Crozier, Adam E. Sundby, Elizabeth Woroszchuk, Fabiano P. Saggioro, Filipe S. Avante, Rodolfo B. dos Reis, Jeremy A. Squire, Jane Bayani
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
The diverse clinical outcomes of prostate cancer have led to the development of gene signature assays predicting disease progression. Improved prostate cancer progression biomarkers are needed as current RNA biomarker tests have varying success for i
Externí odkaz:
https://doaj.org/article/a1fb79af93bd4f06adfa1592578150c9
Autor:
Jane Bayani, Coralie Poncet, Cheryl Crozier, Anouk Neven, Tammy Piper, Carrie Cunningham, Monika Sobol, Stefan Aebi, Kim Benstead, Oliver Bogler, Lissandra Dal Lago, Judith Fraser, Florentine Hilbers, Ingrid Hedenfalk, Larissa Korde, Barbro Linderholm, John Martens, Lavinia Middleton, Melissa Murray, Catherine Kelly, Cecilia Nilsson, Monika Nowaczyk, Stephanie Peeters, Aleksandra Peric, Peggy Porter, Carolien Schröder, Isabel T. Rubio, Kathryn J. Ruddy, Christi van Asperen, Danielle Van Den Weyngaert, Carolien van Deurzen, Elise van Leeuwen-Stok, Joanna Vermeij, Eric Winer, Sharon H. Giordano, Fatima Cardoso, John M. S. Bartlett
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract Male breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to g
Externí odkaz:
https://doaj.org/article/39b74ac02205476a9300ff36cbb33d6d
Autor:
John M S Bartlett, Jane Bayani, Elizabeth N Kornaga, Patrick Danaher, Cheryl Crozier, Tammy Piper, Cindy Q Yao, Janet A Dunn, Paul C Boutros, Robert C Stein, OPTIMA Trial Management Group
Publikováno v:
PLoS ONE, Vol 15, Iss 9, p e0238593 (2020)
Multiparametric assays for risk stratification are widely used in the management of breast cancer, with applications being developed for a number of other cancer settings. Recent data from multiple sources suggests that different tests may provide di
Externí odkaz:
https://doaj.org/article/b8c93de0973747ecbb1372aabe9a7799
Autor:
William Lautert-Dutra, Camila M. Melo, Luiz P. Chaves, Cheryl Crozier, Fabiano P. Saggioro, Rodolfo B. dos Reis, Jane Bayani, Sandro L. Bonatto, Jeremy A. Squire
BackgroundCDK12 inactivation is a predictive biomarker for immune checkpoint blockers (ICB) treatment response in advanced prostate cancer (PCa), but some CDK12-altered patients fail to respond to ICB. Downregulation of MHC expression has been descri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e4475b778923010f582d8950a97922d
https://doi.org/10.1101/2022.04.16.487364
https://doi.org/10.1101/2022.04.16.487364
Autor:
Dan Dion, Giuseppe Viale, Jane Bayani, John M. S. Bartlett, Jonas Bergh, Mary Anne Quintayo, Giancarlo Pruneri, Joema Felipe-Lima, Quang M. Trinh, Fredrik Wärnberg, Ilinca Lungu, Lincoln Stein, Cheryl Crozier
Publikováno v:
Cancer Research. 80:P3-08
Due to breast screening, ductal carcinoma in situ (DCIS) accounts for approximately 25% of all newly diagnosed breast neoplasms. Believed to be a precursor to invasive carcinoma, a significant number of patients diagnosed with DCIS are effectively ma
Autor:
Cheryl Crozier, Lauren Bathurst, Melanie Spears, Jane Bayani, John M. S. Bartlett, Linda Liao
Publikováno v:
Cancer Research. 80:PD2-10
Background: For treatment of metastatic or advanced ER+/HER2- breast cancer, CDK4/6 inhibition (CDKi), including CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib, is now the standard of care. Approximately 25% of patients however will not re
Autor:
Mark Laible, Alfred Etzrodt, Marcus Schmidt, Sebastian Aulmann, Jane Bayani, Ugur Sahin, Cheryl Crozier, Ralph Wirtz, John M. S. Bartlett
Publikováno v:
Cancer Research. 80:P3-07
Background: Current prognostic signatures are based on measurements of numerous targets and require specialized equipment and complex calculations. While the overall prognostic capabilities of the tests may be comparable in ER+/HER2- breast cancer, s
Autor:
John M. S. Bartlett, Megan Hopkins, C. Poncet, Stefan Aebi, Peggy L. Porter, Elise van Leeuwen-Stok, Carolien H.M. van Deurzen, Quang M. Trinh, Kim Benstead, M Nowaczyk, Cecilia Nilsson, Lavinia P. Middleton, Lincoln Stein, Cheryl Crozier, Monika Sobol, Ingrid Hedenfalk, Sharon H. Giordano, Oliver Bogler, Jane Bayani, Joanna Vermeij, Lissandra Dal Lago, Christi J. van Asperen, Melissa Murray, Catherine M. Kelly, Kathryn J. Ruddy, Stéphanie Peeters, Tammy Piper, Carolien P. Schröder, Carrie Cunningham, Florentine Hilbers, Fatima Cardoso, Danielle Van den Weyngaert, Aime Lambert Uwimana, Aleksandra Peric, John W.M. Martens, Eric P. Winer, Isabel T. Rubio, Barbro Linderholm, Larissa A. Korde
Publikováno v:
Cancer Research. 80:P4-10
Introduction: Male breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers (BC) and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Few studies have examined the genomic lan